Synergistic anticancer activity of thiazolo[5,4-b] quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5159-5165

  González Sánchez, Ignacio ^a   Lira Rocha, Alfonso ^a   Navarrete, Andrés ^a   Loza Mejía, Marco A ^a   Coronel Cruz, Cristina ^b   Mendoza Rodríguez, C Adriana ^a   Cerbón, Marco A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antitumor combinations analysis; Cancer; Chemotherapeutic agents; Synergism; Thiazolo 5,4 b quinoline derivative D3CLP

Indexed keywords

[9 [(3 CHLORO)PHENYLAMINE] 2 [3 (DIETHYLAMINE)PROPYLAMINE]THIAZOLO[5,4 B]QUINOLINE]; ANTINEOPLASTIC AGENT; CISPLATIN; IMATINIB; QUINOLINE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL VIABILITY; CYTOTOXICITY TEST; DNA FRAGMENTATION; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; NICK END LABELING; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

AMINOQUINOLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA FRAGMENTATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HELA CELLS; HUMANS; K562 CELLS; MCF-7 CELLS; PIPERAZINES; PYRIMIDINES; TAMOXIFEN; THIAZOLES; UTERINE CERVICAL NEOPLASMS;

EID: 84872567527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM (2010): GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC. International Agency for Research on Cancer. http://globocan.iarc.fr, last accessed 04/02/2012.
2. WHO (2012): Fact sheet No297. Cancer. World Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/index.html, last accessed 03/10/2012.
3. Alvarez-Ibarra C, Fernández-Granda R, Quiroga ML, Carbonell A, Cárdenas F and Giralt E: Synthesis and antitumor evaluation of new thiazolo[5,4-b ]quinoline derivatives. J Med Chem 40: 668-676, 1997.
4. Loza-Mejía MA, Maldonado-Hernández K, Rodríguez- Hernandez F, Rodríguez-Sotres R, González-Sánchez I, Quintero A, Solano JD and Lira-Rocha A: Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives. Bioorg Med Chem 16: 1142-1149, 2008.
5. Loza-Mejía MA, Olvera-Vázquez S, Maldonado-Hernández K, Guadarrama-Salgado T, González-Sánchez I, Rodríguez- Hernández F, Solano JD, Rodríguez-Sotres R and Lira-Rocha A: Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure activity relationship of 9-anilinothiazolo[5,4-b] quinoline derivatives. Bioorg Med Chem 17 : 3266-3277, 2009.
6. Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984.
7. González-Sánchez I, Solano JD, Loza-Mejía MA, Olvera-Vazquez S, Rodríguez-Sotres R, Morán J, Lira-Rocha A and Cerbón MA: Antineoplastic activity of the thiazolo[5,4-b]quinoline derivative D3CLP in K-562 cells is mediated through effector caspases activation. Eur J Med Chem 46: 2102-2108, 2011.
8. Baquiran DC: Lippincott's Cancer Chemotherapy Candbook. Philadelphia: Lippincott Williams & Wilkins, 2001.
9. Chou T-C and Talalay P: Analysis of combined drug effects: A new look at a very old problem. Trends Pharm Sci 4: 450-454, 1983.
10. Tallarida RJ: An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1-7, 2006.
11. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
12. Quintero A, Pelcastre A and Solano JD: Antitumoral activity of new pyrimidine derivatives of sesquiterpene lactones. J Pharm Pharm Sci 2: 108-112, 1999.
13. Garcia-Lopez P, Rodriguez-Dorantes M, Perez-Cardenas E, Cerbon M and Mohar-Betancourt A: Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol 53: 533-540, 2004.
14. Tallarida RJ: Statistical analysis of drug combinations for synergism. Pain 49 : 93-97, 1992.
15. Tallarida RJ, Porreca F and Cowan A: Statistical analysis of drug drug and site site interactions with isobolograms. Life Sci 45: 947-961, 1989.
16. Chou TC and Talalay P: Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
17. Tallarida RJ: Drug synergism: Its detection and applications. J Pharmacol Exp Ther 298: 865-872, 2001.
18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr/Abl-positive cells. Nat Med 2: 561-566, 1996.
19. Deininger MW, Goldman JM, Lydon N and Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR/ABL-positive cells. Blood 90: 3691-3698, 1997.
20. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR/ABL, TEL/ABL, and TEL/PDGFR fusion proteins. Blood 90: 4947-4952, 1997.
21. Olsson-Stromberg U, Aleskog A, Bjornberg A, Hoglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R and Lindhagen E: Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anticancer Drugs 17 : 631-639, 2006.
22. Rostagno P, Caldani C and Lahlou B: Cell cycle expression of steroid receptors determined by image analysis on human breast cancer cell line: A hypothesis on the effects of antiestrogens. Breast Cancer Res Treat 37: 77-87, 1996.
23. Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147(Suppl 1) : S269-276, 2006.
24. Rossi T, Iannuccelli V, Coppi G, Bruni E and Baggio G: Role of the pharmaceutical excipients in the tamoxifen activity on MCF-7 and vero cell cultures. Anticancer Res 29 : 4529-4533, 2009.
25. Wherland S, Deutsch E, Eliason J and Sigler PB: Interactions between polynucleotides and platinum (II) complexes. Biochem Biophys Res Commun 54 : 662-668, 1973.
26. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
27. Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L and Fregona D: Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem Biol Interact 148: 37-48, 2004.
28. Boyd MR (2012): The NCI In Vitro Anticancer Drug Discovery Screen. National Cancer Institute. http://home.ncifcrf.gov/mtdp/catalog/full-text/ paper309/Paper309.pdf, last accessed 10/02/2012
29. Bruce IA, Slevin NJ, Homer JJ, McGown AT and Ward TH: Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 16: 719-726, 2005.
30. Switalska M, Nasulewicz-Goldeman A, Opolska A, Maciejewska M, Kutner A and Wietrzyk J: The in vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anticancer Drugs 23 : 70-80, 2012.
31. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM and Melo JV: Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs. Leukemia 16: 2349-2357, 2002.
32. Argiris A, Wang CX, Whalen SG and DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10: 1409-1420, 2004.
33. Mai Z, Blackburn GL and Zhou JR: Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog 46 : 534-542, 2007.
34. Ropero S, Menéndez JA, Vázquez-Martín A, Montero S, Cortés-Funes H and Colomer R: Trastuzumab plus tamoxifen: Antiproliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86 : 125-137, 2004.
35. Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 115: 3887-3896, 2009.
36. Jurado R, Lopez-Flores A, Alvarez A and Garcia-Lopez P: Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: An in vitro and in vivo study. Oncol Rep 22: 1237-1245, 2009.
37. Horky M, Wurzer G, Kotala V, Anton M, Vojtesek B, Vacha J and Wesierska-Gadek J: Segregation of nucleolar components coincides with caspase-3 activation in cisplatin-treated HeLa cells. J Cell Sci 114 : 663-670, 2001.
38. Liu Y, Xing H, Han X, Shi X, Liang F, Cheng G, Lu Y and Ma D: Apoptosis of HeLa cells induced by cisplatin and its mechanism. J Huazhong Univ Sci Technolog Med Sci 28: 197-199, 2008.